References
- 1. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol 2006; 8: 27-37.
- 2. Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R. Gliomas in adults. Dtsch Arztebl Int 2010; 107: 799-807.
- 3. Kachanov DY, Dobrenkov KV, Shamanskaya TV, Abdullaev RT, Inushkina EV, Varfolomeeva SR, et al. Solid tumors in young children in Moscow Region of Russian Federation. Radiol Oncol 2008; 42: 39-44.
- 4. Chojnacka M, Skowronska-Gardas A, Pedziwiatr K, Morawska-Kaczynska M, Perek M, Perek D. Reirradiation of relapsed brain tumors in children. Rep Pract Oncol Radiother 2012; 17: 32-7.
- 5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classfication of tumours of the central nervous system. Lyon: IARC; 2007.
- 6. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109: 93-108.
- 7. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol 2009; 472: 323-42.
- 8. Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S. A population- based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer 2005; 104: 2798-806.
- 9. Tezcan Y, Koc M. 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors. Radiol Oncol 2011; 45: 213-9.
- 10. Cancer in Slovenia 2008. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2011.
- 11. Catt S, Chalmers A, Fallowfield L. Psychosocial and supportive-care needs in high-grade glioma. Lancet Oncol 2008; 9: 884-91.
- 12. Baur M, Preusser M, Piribauer M, Elandt K, Hassler M, Hudec M, et al. Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience. Radiol Oncol 2010; 44: 113-120.
- 13. Zada G, Bond AE, Wang YP, Giannotta SL, Deapen D. Incidence trends in the anatomic location of primary malignant brain tumors in the United States: 1992-2006. World Neurosurg 2012; 77: 518-24.
- 14. Cancer in Slovenia 2008. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2011.
- 15. Niemiec M, Glogowski M, Tyc-Szczepaniak D, Wierzchowski M, Kepka L. Characteristics of long-term survivors of brain metastases from lung cancer. Rep Pract Oncol Radiother 2011; 16: 49-53.
- 16. Strojan P. Role of radiotherapy in melanoma management. Radiol Oncol 2010: 44: 1-12.
- 17. Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M. Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 2008; 31: 300-5.
- 18. Ziobro M, Rolski J, Grela-Wojewoda A, Zygulska A, Niemiec M. Effects of palliative treatment with temozolomide in patients with high-grade gliomas. Neurol Neurochir Pol 2008; 42: 210-5.
- 19. Dresemann G. Temozolomide in malignant glioma. Onco Targets Ther 2010; 3: 139-46.
- 20. Niyazi M, Schwarz SB, Suchorska B, Belka C. Radiotherapy with and without temozolomide in elderly patients with glioblastoma. Strahlenther Onkol 2012; 188: 154-9.
- 21. Scott JG, Suh JH, Elson P, Barnett GH, Vogelbaum MA, Peereboom DM, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro Oncol 2011; 13: 428-36.
- 22. Ramakrishna R, Kim L, Rostomily R. Glioblastoma: the importance of not being ageist. World Neurosurg 2011; 76: 369-70.
- 23. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 2005; 25: 1-7.
- 24. Purow BW, Schiff D. Glioblastoma genetics: in rapid flux. Discov Med 2010; 9(45): 125-31.
- 25. Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol 2011; 28: 13-24.
- 26. Siebzehnrubl FA, Reynolds BA, Vescovi A, Steindler DA, Deleyrolle LP. The origins of glioma: E Pluribus Unum? Glia 2011; 59: 1135-47.
- 27. Brennan C. Genomic profiles of glioma. Curr Neurol Neurosci Rep 2011; 11: 291-7.
- 28. Sulman EP, Guerrero M, Aldape K. Beyond grade: molecular pathology of malignant gliomas. Semin Radiat Oncol 2009; 19: 142-9.
- 29. Connelly JM, Malkin MG. Environmental risk factors for brain tumors. Curr Neurol Neurosci Rep 2007; 7: 208-14.
- 30. Ng K, Kim R, Kesari S, Carter B, Chen CC. Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. J Neurooncol 2012; 107: 1-12.
- 31. Hentschel SJ, Lang FF. Current surgical management of glioblastoma. Cancer J 2003; 9: 113-25.
- 32. Oszvald A, Güresir E, Setzer M, Vatter H, Senft C, Seifert V, et al. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg 2012; 116: 357-64.
- 33. Vranic A. New developments in surgery of malignant Gliomas. Radiol Oncol 2011; 45: 159-65.
- 34. Stupp R, Mason WP, Van Den Bent MJ, Weller M. Fisher B, Taphoorn M, et al. Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. [Abstract]. J Clin Oncol 2004; 22(14 Suppl): 1S.
- 35. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al; ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62: 564-76.
- 36. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-8.
- 37. Laperriere N, Zuraw L, Cairncross G; Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002; 64: 259-73.
- 38. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
- 39. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
- 40. Bondiau PY, Fauchon F, Jadaud E, Paquis P. Radiothérapie des glioblastomes de l’adulte Neurochirurgie 2010; 56: 486-90.
- 41. Gerstein J, Franz K, Steinbach JP, Seifert V, Rödel C, Weiss C. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution. Strahlenther Onkol 2011; 187: 722-8.
- 42. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000; 1: 459-68.
- 43. Mangiola A, Anile C, Pompucci A, Capone G, Rigante L, De Bonis P. Glioblastoma therapy: going beyond Hercules Columns. Expert Rev Neurother 2010; 10: 507-14.
- 44. Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G, Vecht C. Glioblastoma in adults. Crit Rev Oncol Hematol 2008; 67: 139-52.
- 45. Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 2009; 8: 493-9.
- 46. McDonald MW, Shu HK, Curran WJ Jr, Crocker IR. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys 2011; 79: 130-6.
- 47. Gerstein J, Franz K, Steinbach JP, Seifert V, Fraunholz I, Weiss C, et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol 2010; 97: 382-6.
- 48. van Genugten JA, Leffers P, Baumert BG, Tjon-A-Fat H, Twijnstra A. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol 2010; 96: 249-57.
- 49. Johnson DR, O’Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012; 107: 359-64.
- 50. Smrdel U. Salvage therapy after failure of first line treatment for glioblastoma multiforme. [Abstract]. J Neurooncol 2010; 12(Suppl 3): 44-5.
- 51. Niewald M, Berdel C, Fleckenstein J, Licht N, Ketter R, Rübe C. Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation. Radiat Oncol 2011; 6: 141.
- 52. Niyazi M, Schwarz SB, Suchorska B, Belka C. Radiotherapy with and without temozolomide in elderly patients with glioblastoma. Strahlenther Onkol 2012; 188: 154-9.
- 53. VelnarT, Smrde U, Popovic M, Bunc G. Genetic markers in oligodendroglial tumours. Radiol Oncol 2010; 44: 13-8.
- 54. Ardebili SY, Zajc I, Gole B, Campos B, Herold-Mende C, Drmota S, et al. CD133/prominin1 is prognostic for GBM patient’s survival, but inversely correlated with cysteine cathepsins’ expression in glioblastoma derived spheroids. Radiol Oncol 2011; 45: 102-15.
- 55. Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Arch Neurol 2008; 65: 877-83.
- 56. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-50.
- 57. Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 2012; 116: 341-5.
- 58. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 2012; 106: 147-53.